Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 558Leukemia 281Precursor Cell Lymphoblastic Leukemia-Lymphoma 231Lymphoma 159Myelodysplastic Syndromes 110Burkitt Lymphoma 90Congenital Abnormalities 85Lymphoma, Non-Hodgkin 84Leukemia, Monocytic, Acute 83Leukemia, Myelomonocytic, Acute 81Lymphoma, Large B-Cell, Diffuse 79Leukemia, Erythroblastic, Acute 74Leukemia, Megakaryoblastic, Acute 71Recurrence 69Lymphoma, Mantle-Cell 69Lymphoma, Follicular 48Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Hodgkin Disease 43Lymphoma, Large-Cell, Immunoblastic 36Blast Crisis 36Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 32Myeloproliferative Disorders 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell, Marginal Zone 23Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Leukemia, Basophilic, Acute 22

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Epirubicin 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Observation 2Monatide (IMS 3015) 2Metformin 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Cytarabine × Clear all
NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01656252 2020-11-03

PrE0901

PrECOG, LLC.

Phase 1/2 Terminated
15 enrolled 5 charts
Classical hematologyOther hematologic neoplasm

Jacobs syndrome, Pathologic Complete Response, Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01843179 2017-02-17

Sulindac for Patients With AML

Massachusetts General Hospital

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡